pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Kineret
drug
save

anakinra

Marketedupdated 6mo ago
by Sobi Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval72 co-mentions · 18 sources
  • tagAsthma1 co-mentions · 1 sources

indications

investigational
Rheumatoid Arthritis

all catalysts(0)

nothing on the calendar yet

Trials studying anakinra

  • —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
  • phase2Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Diseaserecruitingn=57
  • phase2A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicitycompletedn=15
  • phase2Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapycompletedn=27
  • phase4A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMFnot yet recruitingn=3
  • phase3A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)active not recruitingn=15
  • phase2Open-label Study of Anakinra in MPS IIIcompletedn=24
  • —Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)completedn=306

News(2)

  • BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
    The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused…
    biospace · 27d ago
  • BMS sheds light on patient death in CAR-T trial, wants to get program back on track
    Bristol Myers Squibb has shared more details with Fierce about the death of a patient who received the pharma's investigational CAR-T in a multiple sclerosis trial.
    fiercebiotech · 27d ago
brand
Kineret
generic
anakinra
indication
Neonatal Onset Multisystem Inflammatory Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?